MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy. 2. Juni 2012 Staehler, MD, Bergmann, L., Grünwald, V., Huschke, T., Keilholz, U., Ohlmann, C., Stöckle, M., Weigang-Koehler, K., Hauswald, K., Schaller, F., Strassl, L., Junker, K., 2012. J Clin Oncol 30(suppl 5; abstr 467). doi: 10.1200/jco.2012.30.5_suppl.467 Abstract Mutation analysis from the REASON, a Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV. Schirmacher, P., Schuette, W., Thomas, M., Eberhardt, W., Graf von der Schulenburg, J.-M., Zaun, S., Dietel, M., 2012. Weiterlesen MARC-2: An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy Staehler, M, Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Schaller, F., Straßl, L., Junker, K., 2012. J Cancer Res Clin Oncol (2012) 138(Suppl 1):… Weiterlesen